SCHEMBL30206043

SCHEMBL30206043

CNc1nc(Nc2ccc(OCCO)cc2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 3/20 0.32
▸ JAK2 O60674 2/20 0.32
▸ P2RX3 P56373 1/20 0.32
▸ BTK Q06187 5/20 0.32
▸ LMNA P02545 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ RIPK2 O43353 3/20 0.32
▸ NOD2 Q9HC29 3/20 0.32
▸ ACVR1 Q04771 2/20 0.32
▸ EGFR P00533 2/20 0.32
▸ JAK3 P52333 2/20 0.31
▸ LCK P06239 1/20 0.31
▸ PDE10A Q9Y233 1/20 0.31
▸ BRD4 O60885 2/20 0.31
▸ JAK1 P23458 2/20 0.31
▸ HDAC1 Q13547 2/20 0.31
▸ RET P07949 1/20 0.31
▸ TYK2 P29597 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ HDAC8 Q9BY41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173617 1.00 SYK (0.32) SYKJAK2P2RX3BTKLMNA
SCHEMBL29173540 0.93 SYK (0.36) SYKJAK2BTKEGFRJAK3
SCHEMBL30206169 0.93 SYK (0.36) SYKJAK2BTKEGFRJAK3
SCHEMBL24944758 0.93 BTK (0.34) SYKJAK2BTKRIPK2NOD2
SCHEMBL30206119 0.91 BTK (0.37) SYKBTKEGFRJAK3LCK
SCHEMBL29173670 0.91 BTK (0.37) SYKBTKEGFRJAK3LCK
SCHEMBL30206336 0.88 SYK (0.36) SYKP2RX3BTKLMNAMAPT
SCHEMBL29173448 0.88 SYK (0.36) SYKP2RX3BTKLMNAMAPT
SCHEMBL29173611 0.88 EGFR (0.40) SYKJAK2EGFRJAK3ABL1
SCHEMBL24944978 0.88 BTK (0.41) SYKJAK2BTKEGFRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 SYK 2532/4885JAK2 486/4885P2RX3 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback